How effective is Rebif for Multiple Sclerosis? (a real world drug study)
Summary:
Overall ratings: 3.3/5 Long term ratings: 3.6/5
This is a phase IV clinical study of how effective Rebif (interferon beta-1a) is for Multiple sclerosis and for what kind of people. The study is created by eHealthMe from 123 Rebif users and is updated continuously.
What is Rebif?
Rebif has active ingredients of interferon beta-1a. It is often used in multiple sclerosis. eHealthMe is studying from 61,126 Rebif users. Check the latest studies of Rebif.
What is Multiple sclerosis?
Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 1,106 drugs and 1,356 conditions by eHealthMe. Check the latest studies of Multiple sclerosis.
123 people are studied for taking Rebif in Multiple sclerosis
Overall effectiveness (number of people):
Long term (1+ years) effectiveness (number of people):
Rebif effectiveness for Multiple sclerosis (number of people):
Overall:
- not at all: 10
- somewhat: 16
- moderate: 34
- high: 47
- very high: 16
Long Term:
- not at all: 2
- somewhat: 11
- moderate: 23
- high: 34
- very high: 15
Gender of people who take Rebif for Multiple sclerosis *:
- female: 82.93 %
- male: 17.07 %
Age of people who take Rebif for Multiple sclerosis *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.81 %
- 20-29: 12.2 %
- 30-39: 21.14 %
- 40-49: 27.64 %
- 50-59: 24.39 %
- 60+: 13.82 %
Who find Rebif more effective for Multiple Sclerosis?
Gender of people who take Rebif for Multiple sclerosis *:
- female: 82.54 %
- male: 17.46 %
Age of people who take Rebif for Multiple sclerosis *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 12.7 %
- 30-39: 17.46 %
- 40-49: 26.98 %
- 50-59: 30.16 %
- 60+: 12.7 %
* Approximation only. Some reports may have incomplete information.
Do you take Rebif?
- You can start a phase IV clinical trial to monitor Rebif safety and effectiveness.How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related publications that referenced our studies:
- Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
- Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
- Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
- Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
Related studies
Alternative drugs to, pros and cons of:
- Rebif (61,126 reports)
Treatments, associated drugs and conditions:
- Multiple sclerosis (799,632 reports)
How the study uses the data?
The study is based on interferon beta-1a (the active ingredients of Rebif) and Rebif (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study neither.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Silodosin and Hyperuricaemia for Men aged 60+ - 4 seconds ago
- Could Oxycodone cause Chronic Thyroiditis? - 4 seconds ago
- Drug interactions of Acetaminophen and Incivek - 5 seconds ago
- Valerian vs. Alprazolam, side effect and effectiveness comparison - 9 seconds ago
- Prilosec and Antidepressant Therapy for Women aged 40-49 - 11 seconds ago
- Prilosec and Depression for Women aged 40-49 - 11 seconds ago
- Could Entyvio cause Kaposi'S Sarcoma? - 15 seconds ago
- Could Prozac cause Atelectasis? - 20 seconds ago
- Could Femara cause Metastases To Adrenals? - 20 seconds ago
- Cellcept and Ards (Acute Respiratory Distress Syndrome) for Men aged 20-29 - 22 seconds ago